A bipartisan group of senators and representatives introduced legislation to establish a National Biopharmaceutical Manufacturing Center of Excellence (COE) to accelerate domestic biomanufacturing innovation, workforce training, and regulatory understanding of emerging manufacturing methods. Sponsors include Sens. Coons and Budd and Reps. Houlahan, Baird, Rouzer and Ross; the effort references recommendations from the National Security Commission on Emerging Biotechnology. The COE would host public‑private collaborations, provide a CGMP‑compliant facility for process scale‑up and testing, and support workforce development—aiming to reduce reliance on foreign supply chains and bolster national health and economic security. The bill signals growing legislative momentum to shore up U.S. biomanufacturing capacity amid global competition.